As of 2026-03-26, the EV/EBITDA ratio of Castle Biosciences Inc (CSTL) is -341.64. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CSTL's latest enterprise value is 647.40 mil USD. CSTL's TTM EBITDA according to its financial statements is -1.89 mil USD. Dividing these 2 quantities gives us the above CSTL EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 9.3x - 11.9x | 10.1x |
| Forward P/E multiples | 9.2x - 9.7x | 9.6x |
| Fair Price | 2.98 - 2.95 | 2.94 |
| Upside | -88.2% - -88.4% | -88.4% |
| Date | EV/EBITDA |
| 2026-03-24 | -341.64 |
| 2026-03-23 | -347.91 |
| 2026-03-20 | -336.14 |
| 2026-03-19 | -347.13 |
| 2026-03-18 | -345.79 |
| 2026-03-17 | -350.26 |
| 2026-03-16 | -349.17 |
| 2026-03-13 | -344.93 |
| 2026-03-12 | -341.16 |
| 2026-03-11 | -353.87 |
| 2026-03-10 | -361.25 |
| 2026-03-09 | -367.84 |
| 2026-03-06 | -369.40 |
| 2026-03-05 | -381.80 |
| 2026-03-04 | -385.88 |
| 2026-03-03 | -376.46 |
| 2026-03-02 | -383.05 |
| 2026-02-27 | -407.84 |
| 2026-02-26 | -444.08 |
| 2026-02-25 | -427.61 |
| 2026-02-24 | -413.65 |
| 2026-02-23 | -397.96 |
| 2026-02-20 | -402.19 |
| 2026-02-19 | -435.61 |
| 2026-02-18 | -472.17 |
| 2026-02-17 | -468.24 |
| 2026-02-13 | -464.01 |
| 2026-02-12 | -444.40 |
| 2026-02-11 | -451.30 |
| 2026-02-10 | -451.77 |
| 2026-02-09 | -449.57 |
| 2026-02-06 | -457.73 |
| 2026-02-05 | -452.24 |
| 2026-02-04 | -492.40 |
| 2026-02-03 | -554.84 |
| 2026-02-02 | -563.16 |
| 2026-01-30 | -561.90 |
| 2026-01-29 | -558.30 |
| 2026-01-28 | -563.79 |
| 2026-01-27 | -616.03 |
| 2026-01-26 | -619.17 |
| 2026-01-23 | -606.62 |
| 2026-01-22 | -605.21 |
| 2026-01-21 | -586.85 |
| 2026-01-20 | -584.97 |
| 2026-01-16 | -571.63 |
| 2026-01-15 | -583.24 |
| 2026-01-14 | -583.55 |
| 2026-01-13 | -565.83 |
| 2026-01-12 | -566.14 |